BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8958300)

  • 1. CD44 expression in benign and malignant nevomelanocytic lesions.
    Leigh CJ; Palechek PL; Knutson JR; McCarthy JB; Cohen MB; Argenyi ZB
    Hum Pathol; 1996 Dec; 27(12):1288-94. PubMed ID: 8958300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD44 and variants in melanocytic skin neoplasms.
    Schaider H; Soyer HP; Heider KH; Hofmann-Wellenhof R; Zatloukal K; Smolle J; Kerl H
    J Cutan Pathol; 1998 Apr; 25(4):199-203. PubMed ID: 9609138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD44 and melanocytic tumors: a possible role for standard CD44 in the epidermotropic spread of melanoma.
    Fernández-Figueras MT; Ariza A; Calatrava A; Puig L; Fernández-Vasalo A; Ferrándiz C
    J Cutan Pathol; 1996 Apr; 23(2):133-9. PubMed ID: 8721447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of CD44 isoforms and beta 1,6-branched oligosaccharides in human malignant melanoma is correlated with tumor progression but not with metastatic potential.
    Seelentag WK; Böni R; Günthert U; Futo E; Burg G; Heitz PU; Roth J
    J Cutan Pathol; 1997 Apr; 24(4):206-11. PubMed ID: 9138110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moesin and CD44 expression in cutaneous melanocytic tumours.
    Ichikawa T; Masumoto J; Kaneko M; Saida T; Sagara J; Taniguchi S
    Br J Dermatol; 1998 May; 138(5):763-8. PubMed ID: 9666819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD44 loss in gastric stromal tumors as a prognostic marker.
    Montgomery E; Abraham SC; Fisher C; Deasel MR; Amr SS; Sheikh SS; House M; Lilliemoe K; Choti M; Brock M; Ephron DT; Zahuruk M; Chadburn A
    Am J Surg Pathol; 2004 Feb; 28(2):168-77. PubMed ID: 15043305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased levels of CD44 protein and mRNA in prostate carcinoma. Correlation with tumor grade and ploidy.
    Kallakury BV; Yang F; Figge J; Smith KE; Kausik SJ; Tacy NJ; Fisher HA; Kaufman R; Figge H; Ross JS
    Cancer; 1996 Oct; 78(7):1461-9. PubMed ID: 8839552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of CD44s and CD44 splice variants in human melanoma.
    Ranuncolo SM; Ladeda V; Gorostidy S; Morandi A; Varela M; Lastiri J; Loria D; Del Aguila R; Joffé EB; Pallotta G; Puricelli L
    Oncol Rep; 2002; 9(1):51-6. PubMed ID: 11748454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of CD44 isoforms correlates with the metastatic potential of osteosarcoma.
    Kim HS; Park YB; Oh JH; Jeong J; Kim CJ; Lee SH
    Clin Orthop Relat Res; 2002 Mar; (396):184-90. PubMed ID: 11859242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
    Nasr MR; El-Zammar O
    Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of CD44 splice variants in formalin-fixed, paraffin-embedded specimens of human skin cancer.
    Dietrich A; Tanczos E; Vanscheidt W; Schöpf E; Simon JC
    J Cutan Pathol; 1997 Jan; 24(1):37-42. PubMed ID: 9027631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD44 expression in melanocytic lesions: a marker of malignant progression?
    Harwood CA; Green MA; Cook MG
    Br J Dermatol; 1996 Dec; 135(6):876-82. PubMed ID: 8977706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
    Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
    Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative assessment of expression of cell adhesion molecule (CD44) splice variants: CD44 standard (CD44s) and v5, v6 isoforms in oral leukoplakias: an immunohistochemical study.
    Godge PY; Poonja LS
    Indian J Dent Res; 2011; 22(3):493-4. PubMed ID: 22048598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of CD44S expression in renal clear cell carcinomas with subsequent tumor progression or recurrence.
    Gilcrease MZ; Guzman-Paz M; Niehans G; Cherwitz D; McCarthy JB; Albores-Saavedra J
    Cancer; 1999 Dec; 86(11):2320-6. PubMed ID: 10590373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD44 expression in sinonasal melanomas: is loss of isoform expression associated with advanced tumour stage?
    Regauer S; Ott A; Berghold A; Beham A
    J Pathol; 1999 Jan; 187(2):184-90. PubMed ID: 10365093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD44 expression in sinonasal inverted papillomas and associated squamous cell carcinoma.
    Ingle R; Jennings TA; Goodman ML; Pilch BZ; Bergman S; Ross JS
    Am J Clin Pathol; 1998 Mar; 109(3):309-14. PubMed ID: 9495203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas.
    Tran TA; Kallakury BV; Sheehan CE; Ross JS
    Hum Pathol; 1997 Jul; 28(7):809-14. PubMed ID: 9224749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of CD44 variant isoforms and association to the benign form of endocrine pancreatic tumours.
    Imam H; Eriksson B; Oberg K
    Ann Oncol; 2000 Mar; 11(3):295-300. PubMed ID: 10811495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Typical, dysplastic, congenital, and Spitz nevi: a comparative immunohistochemical study.
    Palazzo J; Duray PH
    Hum Pathol; 1989 Apr; 20(4):341-6. PubMed ID: 2703228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.